Clinical Trials Logo

Clinical Trial Summary

Based on preclinical data, the investigators hypothesize that IRAK4 inhibition cripples tumor-intrinsic survival signaling and effectively overcomes the desmoplastic and immune-suppressive TME to render chemo- and immunotherapies effective in gastrointestinal (GI) malignancy. Therefore, this trial is designed to evaluate combination of CA-4948 and standard chemo/immunotherapy in untreated gastric and esophageal cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05187182
Study type Interventional
Source Washington University School of Medicine
Contact Haeseong Park, M.D., MPH
Phone 314-747-7510
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date February 28, 2022
Completion date April 30, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05052931 - Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer Phase 2
Recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Active, not recruiting NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Recruiting NCT04249739 - Pembrolizumab + Capecitabine´╝ĆOxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04062656 - Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG Phase 2
Recruiting NCT04354662 - Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer Phase 2
Recruiting NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Not yet recruiting NCT03273920 - Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT04553692 - Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers Phase 1
Active, not recruiting NCT04842916 - InteGRAtive Analysis of tuMor, Microenvironment, immunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer
Recruiting NCT04342910 - Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC Phase 3